L03RD1 + L03RD2 + CT-L03
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus (T2DM)
Conditions
Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Aug 18, 2025 → Oct 23, 2025
NCT ID
NCT07158346About L03RD1 + L03RD2 + CT-L03
L03RD1 + L03RD2 + CT-L03 is a phase 1 stage product being developed by Celltrion for Type 2 Diabetes Mellitus (T2DM). The current trial status is completed. This product is registered under clinical trial identifier NCT07158346. Target conditions include Type 2 Diabetes Mellitus (T2DM).
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus (T2DM) were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07158346 | Phase 1 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus (T2DM)